Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Larson

Showing results (141-150 of 208) with videos related to

Pageof 21
Sort By:
Mutation Research|April 1, 1989
Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemiaJ L Schwartz, T Karrison, M M Le Beau, et al.
Bone Marrow Transplantation|January 1, 1992
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantationR B Geller, S Myers, S Devine, et al.
British Journal of Haematology|October 1, 1992
The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup studyR A Larson, R S Day, N Azarnia, et al.
Leukemia|May 1, 1996
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemiaJ Anastasi, J Feng, J I Dickstein, et al.
American Journal of Hematology|April 1, 1993
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemiaA Raza, H D Preisler, Y Q Li, et al.
Blood|December 15, 1990
t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemiaC M Rubin, R A Larson, J Anastasi, et al.
British Journal of Haematology|November 1, 1991
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failureH D Preisler, R A Larson, A Raza, et al.
Leukemia & Lymphoma|October 1, 1992
A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropeniaS E Myers, S M Devine, R L Topper, et al.
Science (New York, N.Y.)|February 28, 1986
Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disordersM M Le Beau, C A Westbrook, M O Diaz, et al.
The American Journal of Surgical Pathology|April 1, 1990
Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35)M A Bitter, W A Franklin, R A Larson, et al.
Pageof 21

Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
Mutation Research|April 1, 1989
Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemiaJ L Schwartz, T Karrison, M M Le Beau, et al.
Bone Marrow Transplantation|January 1, 1992
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantationR B Geller, S Myers, S Devine, et al.
British Journal of Haematology|October 1, 1992
The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup studyR A Larson, R S Day, N Azarnia, et al.
Leukemia|May 1, 1996
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemiaJ Anastasi, J Feng, J I Dickstein, et al.
American Journal of Hematology|April 1, 1993
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemiaA Raza, H D Preisler, Y Q Li, et al.
Blood|December 15, 1990
t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemiaC M Rubin, R A Larson, J Anastasi, et al.
British Journal of Haematology|November 1, 1991
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failureH D Preisler, R A Larson, A Raza, et al.
Leukemia & Lymphoma|October 1, 1992
A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropeniaS E Myers, S M Devine, R L Topper, et al.
Science (New York, N.Y.)|February 28, 1986
Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disordersM M Le Beau, C A Westbrook, M O Diaz, et al.
The American Journal of Surgical Pathology|April 1, 1990
Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35)M A Bitter, W A Franklin, R A Larson, et al.
Pageof 21